This dual-action approach addresses multiple facets of the underlying pathophysiology of obesity and insulin resistance, making it a promising therapeutic option for individuals struggling with weight loss and metabolic dysregulation
/The authors/ have recently held a pre-IND meeting with the FDA and /their/ goal is to advance this cyanide antagonist to the clinic by validation of animal models, demonstrate efficacy of sulfanegen in these animal models and perform the required GLP pharmacokinetic and safety evaluation required for clinical trials
Animal Model:8-10 male C57BL/6J mice [1] Dosage:50 mg/kg Administration:i.p., a single dose for 28 or 12 days Result:Displayed a more oxidative muscle phenotype, increased the complex I (NDUFB8) and complex V (ATP5A) protein expression in the gastrocnemius muscle and cytochrome C, mitochondria content and oxidative type IIa muscle fibers lavels in mice
(59(6)):859-861 doi:10.2169/internalmedicine.3695-19
Hip Tendinopathy Restores mobility and reduces pain
Iontophoresis transcorneal delivery technique for transepithelial corneal collagen crosslinking with riboflavin in a rabbit model